Home

West Pharmaceutical Services, Inc. Common Stock (WST)

214.55
+3.96 (1.88%)
NYSE · Last Trade: Apr 26th, 8:53 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close210.59
Open214.70
Bid190.33
Ask217.63
Day's Range209.38 - 214.76
52 Week Range187.43 - 372.79
Volume905,947
Market Cap15.51B
PE Ratio (TTM)33.68
EPS (TTM)6.4
Dividend & Yield0.8400 (0.39%)
1 Month Average Volume1,063,913

Chart

About West Pharmaceutical Services, Inc. Common Stock (WST)

West Pharmaceutical Services is a prominent global leader in the design and manufacturing of components and systems for the delivery of injectable drugs. The company specializes in producing high-quality materials such as stoppers, seals, and prefillable syringes, which are essential for the safe and efficient administration of pharmaceuticals. West Pharmaceutical Services partners with pharmaceutical and biotechnology companies to deliver innovative solutions that enhance drug efficacy and patient safety, focusing on advancing healthcare through its cutting-edge technologies and services. With a commitment to excellence and a strong emphasis on sustainability, West continually strives to improve the standards of drug delivery within the healthcare industry. Read More

News & Press Releases

West Pharmaceutical Defies Doubters: EPS Jumps, Outlook Raised Despite Tariff Dragbenzinga.com
West Pharmaceutical topped Q1 estimates and raised 2025 guidance, citing stronger device demand and improved inventory trends across key markets.
Via Benzinga · April 24, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
Via Chartmill · April 24, 2025
West Pharmaceutical Services (NYSE:WST) Exceeds Q1 Expectations, Stock Soars
Healthcare products company West Pharmaceutical Services (NYSE:WST) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $698 million. The company’s full-year revenue guidance of $2.96 billion at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $1.45 per share was 18.1% above analysts’ consensus estimates.
Via StockStory · April 24, 2025
Insights Ahead: West Pharmaceutical Servs's Quarterly Earningsbenzinga.com
Via Benzinga · April 23, 2025
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?benzinga.com
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade tensions boosts risk sentiment.
Via Benzinga · April 24, 2025
Earnings Scheduled For April 24, 2025benzinga.com
Via Benzinga · April 24, 2025
West Pharmaceutical Services Earnings: What To Look For From WST
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting results tomorrow before market open. Here’s what investors should know.
Via StockStory · April 23, 2025
These S&P500 stocks are moving in today's sessionchartmill.com
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · April 21, 2025
What's going on in today's session: S&P500 moverschartmill.com
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · April 17, 2025
These S&P500 stocks are gapping in today's sessionchartmill.com
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · April 17, 2025
Top S&P500 movers in Thursday's pre-market sessionchartmill.com
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
Via Chartmill · April 17, 2025
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.chartmill.com
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today.
Via Chartmill · April 9, 2025
Which S&P500 stocks are gapping on Tuesday?chartmill.com
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
Via Chartmill · April 8, 2025
3 Reasons to Sell WST and 1 Stock to Buy Instead
West Pharmaceutical Services has gotten torched over the last six months - since October 2024, its stock price has dropped 29.3% to $202.47 per share. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Via StockStory · April 8, 2025
3 S&P 500 Stocks That Concern Us
The S&P 500 is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · April 3, 2025
How Is The Market Feeling About West Pharmaceutical Servs?benzinga.com
Via Benzinga · March 28, 2025
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers.
Via StockStory · March 25, 2025
This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · March 18, 2025
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season.
Via StockStory · March 18, 2025
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks, starting with UFP Technologies (NASDAQ:UFPT).
Via StockStory · March 13, 2025
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers.
Via StockStory · March 12, 2025
Florida Rep. Jared Moskowitz Sold Up to $15K Worth of West Pharmaceutical Servs Stockbenzinga.com
Via Benzinga · March 7, 2025
Explore the top gainers and losers within the S&P500 index in today's session.chartmill.com
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · February 28, 2025
Friday's session: top gainers and losers in the S&P500 indexchartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · February 28, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · February 24, 2025